Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.91−0.54 (-4.34%)
Close on Nov 17, 2026Market cap $1.54BP/E –Yield –
Mesoblast price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Mesoblast's price to sales ratio was 14.7× on Nov 11, 2026, against 121.0× a year earlier. Over the last 5 years it ranged from 14.7× to 336.7×, with a median of 69.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.7× | −112.0 |
| 2025 | Dec 31, 2025 | 126.7× | −204.3 |
| 2024 | Dec 31, 2024 | 331.0× | +308.2 |
| 2023 | Dec 29, 2023 | 22.8× | −27.0 |
| 2022 | Dec 30, 2022 | 49.8× | −11.6 |
| 2021 | Dec 31, 2021 | 61.4× | +4.5 |
| 2020 | Dec 31, 2020 | 56.9× | +23.7 |
| 2019 | Dec 31, 2019 | 33.1× | +19.1 |
| 2018 | Dec 31, 2018 | 14.1× | −179.2 |
| 2017 | Dec 29, 2017 | 193.2× | +184.1 |
| 2016 | Dec 30, 2016 | 9.2× | – |
See a number that looks wrong?